Compare iShares Core S&P 500 ETF (IVV) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core S&P 500 ETF vs McKesson Corporation — how do they compare? iShares Core S&P 500 ETF trades at $776.87, while McKesson Corporation trades at $895.52 (market cap $105.14B). The key difference: McKesson Corporation pays a 0.42% dividend while iShares Core S&P 500 ETF pays none, and iShares Core S&P 500 ETF is trading nearer its 52-week high, McKesson Corporation nearer its low. Which is the better fit depends on your goals.
| IVV | MCK | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $776.81 | $995.69 |
52-Week Low | $634.93 | $659.01 |
Market Cap | — | $105.14B |
Enterprise Value | — | $111.67B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $776.38, down slightly by 0.04% amid broader market caution ahead of inflation data. The ETF shows a bullish technical signal with moving averages supporting upside, but oscillators are neutral and RSI levels indicate overbought conditions. Recent news highlights institutional interest, with First Bank & Trust increasing its stake, while JPMorgan raised its S&P 500 target to 8,000 for 2026, citing strong earnings and AI-driven growth (JPMorgan report, August 10, 2026).
Outlook remains positive due to robust corporate earnings and AI investments, but risks include high valuations and potential pullbacks from overbought levels. Investors should weigh the ETF's diversification benefits against market volatility and economic data sensitivity.
McKesson (MCK) trades at $879.87, up 1.18% today, with strong momentum from recent earnings beats and raised guidance. The stock shows bullish technical signals, supported by robust revenue growth and solid cash flow generation. Recent news highlights strength in specialty drugs and oncology, driving positive sentiment.
Outlook remains favorable with a consensus price target of $990.67, though thin profit margins and high liabilities pose risks. Continued execution on growth initiatives and cost discipline are key for sustained upside, while macroeconomic pressures and competitive dynamics require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
